What Happened?
Forest Lake, MN-based Steve Goedeke as Chief Executive Officer
About the Company
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
About the Person
Steve Goedekes extensive experience spans implantable defibrillators, pacemakers, therapies for heart failure, device design, and wireless communications. Before joining Cardionomic as President and Chief Executive Officer , Goedeke was President and Chief Executive Officer at Denali Medical II and previously served as a Senior Director within Medtronics Cardiac Rhythm Disease Management division. He is a Bakken Fellow and was largely responsible for the creation of the MICS wireless system. He is also a two-time recipient of Medtronics Star of Excellence and was granted The Chairmans Award for Outstanding Initiative. Before his 17 years at Medtronic, Goedeke held various technical and business development roles at Hewlett-Packard. Goedeke is a named inventor on 25 patents and holds a B.S in electrical engineering from Washington University in St. Louis and a M.S. in electrical engineering from the University of Illinois at Urbana-Champaign.
Info Source
News
Short Profile